


## CLAIMS

Claim 1. A compound of formula (I):



5 wherein:


$R^1$  is a group of formula O-L-A;

L is  $-(CHR^{12})_m-$ ;

each  $R^{12}$  is independently H or  $C_{1-4}$ alkyl;

m is 1, 2 or 3;

10 A is:



v is 0, 1 or 2;

$R^{9a}$  is H,  $C_{1-4}$ alkyl or  $C_{1-4}$ haloalkyl;

$R^{9b}$  is H,  $C_{1-4}$ alkyl or  $C_{1-4}$ haloalkyl;

15  $R^{9c}$  is  $C_{1-4}$ alkyl or  $C_{1-4}$ haloalkyl;

$R^{9d}$  is H,  $C_{1-4}$ alkyl or  $C_{1-4}$ haloalkyl;

$R^{10}$  is H,  $C_{1-4}$ alkyl or  $C_{1-4}$ haloalkyl;

$R^{11}$  is H, halo, CN,  $C_{1-4}$ alkyl,  $C_{1-4}$ haloalkyl,  $C_{1-4}$ alkoxy or  $C_{1-4}$ haloalkoxy;

s is 0, 1, 2 or 3;

20 each  $R^2$  is independently F, Cl, Br,  $OCH_3$ ,  $OCF_3$  or  $C_{1-4}$ alkyl optionally substituted by up to 3 halogen groups;

Y is CH or  $C_{1-4}$ alkyl;

$R^3$  is H or  $C_{1-4}$ alkyl;

$R^4$  is H or  $C_{1-4}$ alkyl;

25  $R^5$  is H or  $C_{1-4}$ alkyl;

$R^6$  is H or  $C_{1-4}$ alkyl;  
 $q$  is 0 or 1;  
 $R^7$  is H or methyl;  
 $R^8$  is H or methyl;  
 5 or  $R^3$  and  $R^5$  and the intervening atoms form a 3 to 7 membered non-aromatic heterocycle composed of the intervening atoms and bond, or the intervening atoms and  $-(CHR^a)_r$ ; or the  $R^7$  group and the  $R^5$  group and the intervening atoms form a 3 to 7 membered non-aromatic heterocycle composed of the intervening atoms and  $-(CHR^a)_r$ ;  
 $r$  is 1, 2, 3, 4 or 5; and  
 10  $R^a$  is hydrogen or methyl;  
 or a salt and/or solvate thereof.

Claim 2. The compound, salt and/or solvate thereof according to claim 1, wherein each  $R^{12}$  is H.

15 Claim 3. The compound, salt and/or solvate thereof according to claim 1 or claim 2, wherein  $m$  is 2.

Claim 4. The compound, salt and/or solvate thereof according to any one of claims 1 to  
 20 3, wherein  $v$  is 0.

Claim 5. The compound, salt and/or solvate thereof according to any one of claims 1 to 4, wherein  $R^{9c}$  is  $C_{1-4}$ alkyl, such as methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl or *tert*-butyl, for example methyl, *iso*-propyl or *tert*-butyl.


25 Claim 6. The compound, salt and/or solvate thereof according to claim 5, wherein  $R^{9c}$  is methyl; or wherein  $R^{9c}$  is *iso*-propyl; or wherein  $R^{9c}$  is *tert*-butyl.

Claim 7. The compound, salt and/or solvate thereof according to any one of claims 1 to  
 30 6, wherein  $R^{9d}$  is H; or wherein  $R^{9d}$  is  $C_{1-4}$ alkyl, such as methyl.

Claim 8. The compound, salt and/or solvate thereof according to any one of claims 1 to 4, wherein  $R^{9c}$  is *tert*-butyl and  $R^{9d}$  is H; or wherein  $R^{9c}$  is methyl and  $R^{9d}$  is methyl.

35 Claim 9. The compound, salt and/or solvate thereof according to any one of claims 1 to 8, wherein  $R^{10}$  is  $C_{1-4}$ alkyl, such as methyl.

- Claim 10. The compound, salt and/or solvate thereof according to any one of claims 1 to 9, wherein  $R^{11}$  is  $C_{1-4}$ alkyl, such as methyl.
- 5 Claim 11. The compound, salt and/or solvate thereof according to any one of claims 1 to 10, wherein  $s$  is 1; or wherein  $s$  is 2.
- Claim 12. The compound, salt and/or solvate thereof according to any one of claims 1 to 11, wherein at least one  $R^2$  is halo such as Cl, F or Br, such as Cl or F, especially F.
- 10 Claim 13. The compound, salt and/or solvate thereof according to any one of claims 1 to 12, wherein  $Y$  is CH.
- Claim 14. The compound, salt and/or solvate thereof according to any one of claims 1 to 13, wherein  $R^3$  is H; and/or wherein  $R^4$  is H.
- 15 Claim 15. The compound, salt and/or solvate thereof according to any one of claims 1 to 14, wherein  $R^5$  is H; or wherein  $R^5$  is  $C_{1-4}$ alkyl, such as methyl.
- Claim 16. The compound, salt and/or solvate thereof according to any one of claims 1 to 20 15, wherein  $R^6$  is H; or wherein  $R^6$  is  $C_{1-4}$ alkyl, such as methyl.
- Claim 17. The compound, salt and/or solvate thereof according to any one of claims 1 to 16, wherein  $R^5$  is methyl and  $R^6$  is H.
- 25 Claim 18. The compound, salt and/or solvate thereof according to any one of claims 1 to 17, wherein  $q$  is 0.
- Claim 19. The compound, salt and/or solvate thereof according to any one of claims 1 to 18, which is a compound of formula (IA):



(IA),

wherein:

R<sup>2a</sup> is H or F;

R<sup>2b</sup> is F;

5 R<sup>5a</sup> is H or methyl;

R<sup>6a</sup> is H or methyl;

R<sup>9ca</sup> is methyl, *iso*-propyl or *tert*-butyl;

R<sup>9cb</sup> is H or methyl;

R<sup>10a</sup> is methyl; and

10 R<sup>11a</sup> is methyl;

provided that when R<sup>2a</sup> is H, R<sup>9cb</sup> is H;

or a salt and/or solvate thereof.

15 Claim 20. The compound, salt and/or solvate thereof according to claim 19, wherein R<sup>2a</sup> is F; and/or wherein R<sup>5a</sup> is H; and/or wherein R<sup>6a</sup> is methyl.

Claim 21. The compound, salt and/or solvate thereof according to claim 19 or claim 20, wherein R<sup>9cb</sup> is H.

20 Claim 22. The compound, salt and/or solvate thereof according to claim 19 or claim 20, wherein R<sup>9ca</sup> is *tert*-butyl and R<sup>9cb</sup> is H.

Claim 23. The compound, salt and/or solvate thereof according to claim 19 or claim 20, wherein R<sup>9ca</sup> is methyl and R<sup>9cb</sup> is methyl.

25


Claim 24. The compound, salt and/or solvate thereof according to claim 1, which is a compound selected from the group consisting of:

- 1-{4-[2-(5-fluoro-2-{3-[(methylamino)methyl]imidazo[1,2-a]pyridin-6-yl}phenoxy)ethyl]-1,5-dimethyl-1H-pyrazol-3-yl}ethan-1-ol;
- 1-(4-(2-(2-(3-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-5-fluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)ethan-1-ol;
- 5 (isomer 1) 1-(4-(2-(2-(3-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-5-fluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)ethan-1-ol;
- (isomer 2) 1-(4-(2-(2-(3-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-5-fluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)ethan-1-ol;
- 10 1-{4-[2-(2,3-difluoro-6-{3-[(methylamino)methyl]imidazo[1,2-a]pyridin-6-yl}phenoxy)ethyl]-1,5-dimethyl-1H-pyrazol-3-yl}ethan-1-ol;
- 1-(4-(2-(6-(3-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-2,3-difluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)ethan-1-ol;
- 1-(4-(2-(2-(3-(2-aminoethyl)imidazo[1,2-a]pyridin-6-yl)-5-fluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)ethan-1-ol;
- 15 1-(4-(2-(5-fluoro-2-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol;
- (isomer 1) 1-(4-(2-(5-fluoro-2-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol;
- (isomer 2) 1-(4-(2-(5-fluoro-2-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol;
- 20 1-(4-(2-(2-(3-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-5-fluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol;
- 1-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol;
- 25 (isomer 1) 1-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol;
- (isomer 2) 1-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol;
- (isomer 1) 1-(4-(2-(6-(3-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-2,3-difluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol;
- 30 (isomer 2) 1-(4-(2-(6-(3-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-2,3-difluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol;
- 1-(4-(2-(6-(3-(aminomethyl)imidazo[1,2-a]pyridin-6-yl)-2,3-difluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol;
- 35 2-(4-(2-(5-fluoro-2-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)propan-2-ol;

- 2-(4-(2-(2-(3-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-5-fluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)propan-2-ol;  
 2-[4-(2-{6-[3-(aminomethyl)imidazo[1,2-a]pyridin-6-yl]-2,3-difluorophenoxy}ethyl)-1,5-dimethyl-1H-pyrazol-3-yl]propan-2-ol;  
 5 2-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)propan-2-ol;  
 2-{4-[2-(2-{3-[(ethylamino)methyl]imidazo[1,2-a]pyridin-6-yl}-5-fluorophenoxy)ethyl]-1,5-dimethyl-1H-pyrazol-3-yl}propan-2-ol;  
 2-(4-(2-(2-(3-(2-aminoethyl)imidazo[1,2-a]pyridin-6-yl)-5-fluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)propan-2-ol;  
 10 1-(4-(2-(2-(3-((dimethylamino)methyl)imidazo[1,2-a]pyridin-6-yl)-5-fluorophenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2-methylpropan-1-ol; and  
 1-{4-[2-(2,3-difluoro-6-{3-[(methylamino)methyl]imidazo[1,2-a]pyridin-6-yl}phenoxy)ethyl]-1,5-dimethyl-1H-pyrazol-3-yl}-2-methylpropan-1-ol;  
 15 or a salt and/or solvate of any one thereof.


Claim 25. The compound, salt and/or solvate thereof according to claim 1, which is 1-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol:

20




or a salt and/or solvate thereof.

- Claim 26. The compound, salt and/or solvate thereof according to claim 25, which is 1-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol, wherein the compound is the isomer having the stereochemical arrangement of:
- 25



or a salt and/or solvate thereof.


Claim 27. The compound, salt and/or solvate thereof according to claim 25, which is 1-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol, wherein the compound is the isomer having the stereochemical arrangement of:



or a salt and/or solvate thereof.


10

Claim 28. The compound, salt and/or solvate thereof according to claim 25, which is the pharmaceutically acceptable salt of 1-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol:




15

Claim 29. The compound, salt and/or solvate thereof according to claim 25, which is 1-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)-2,2-dimethylpropan-1-ol:




Claim 30. The compound, salt and/or solvate thereof according to claim 1, which is 2-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)propan-2-ol:




or a salt and/or solvate thereof.

Claim 31. The compound, salt and/or solvate thereof according to claim 30, which is the pharmaceutically acceptable salt of 2-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)propan-2-ol:



Claim 32. The compound, salt and/or solvate thereof according to claim 30, which is 2-(4-(2-(2,3-difluoro-6-(3-((methylamino)methyl)imidazo[1,2-a]pyridin-6-yl)phenoxy)ethyl)-1,5-dimethyl-1H-pyrazol-3-yl)propan-2-ol:



Claim 33. The compound, salt and/or solvate thereof according to any one of claims 1 to 18, wherein s is 2 and each R<sup>2</sup> is F.

5

Claim 34. A pharmaceutical composition comprising the compound, pharmaceutically acceptable salt and/or solvate according to any one of claims 1 to 33 and a pharmaceutically acceptable carrier.


10 Claim 35. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 33, or pharmaceutical composition according to claim 34, for use as a medicament.

15 Claim 36. The compound, pharmaceutically acceptable salt and/or solvate, or pharmaceutical composition, for use according to claim 35, wherein the disease or disorder is a hyperproliferative disorder, and wherein the hyperproliferative disorder is cancer.

20 Claim 37. The compound, pharmaceutically acceptable salt and/or solvate, or pharmaceutical composition, for use according to claim 36, wherein the cancer is breast cancer, bladder cancer, lung cancer, prostate cancer, kidney cancer, esophageal carcinoma, colorectal cancer, gallbladder carcinoma, brain tumor, lymphoma, leukemia or neuroblastoma.

Claim 38. A compound selected from the group consisting of:

- a compound of formula (II)




(II)

;


25

- a compound of formula (III):




wherein P is  $C_{1-4}$ alkyl or  $C_{1-4}$ alkoxy;

- a compound of formula (V):




5

- a compound of formula (VI)



; and

- a compound of formula (VII)



wherein P is C<sub>1-4</sub>alkoxy;

or a salt, such as pharmaceutically acceptable salt thereof,

wherein s, q, v, L, A, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9a</sup> and R<sup>9b</sup> are as defined in claim 1.


5

Claim 39. Use of a compound, salt or solvate thereof according to any one of claims 1 to 33 as a payload for an antibody drug conjugate.

Claim 40. An antibody drug conjugate or a salt thereof, comprising as payload a compound or salt and/or solvate thereof according to any one of claims 1 to 33.

10


Claim 41. The ADC or a salt thereof according claim 40 which has the following formula:



wherein:

Ab is an antibody;

- 5  $\text{NMT}$  represents an NMT inhibitor such as a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 33; and p is an integer between 1 and 10; or which has the following formula:



wherein:

Ab is an antibody;



represents an NMT inhibitor such as a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 33; and

p is an integer between 1 and 10.

5 Claim 42. The ADC or a salt thereof according to claim 40 or claim 41 wherein the antibody binds to HER2.

Claim 43. The ADC or a salt thereof according to claim 42, wherein the antibody is  
10 trastuzumab, pertuzumab, margetuximab, ertumaxomab, MM-111, MCLA-128, ZW25, MDX-210, ado-trastuzumab or fam-trastuzumab.

Claim 44. The ADC or a salt thereof according to claim 43, wherein the antibody is trastuzumab.

15 Claim 45. The ADC or a salt thereof according to claim 42, wherein the the antibody has the CDRs of the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2.

Claim 46. The ADC or a salt thereof according to claim 40 or claim 41 wherein the  
20 antibody binds to CD276 (B7-H3).

Claim 47. The ADC or a salt thereof according to any one of claims 41 to 46, wherein p is an integer between 4 and 6.

Claim 48. The ADC or a salt thereof according to any one of claims 40 to 47, wherein the  
25 antibody of the antibody drug conjugate is bound via a sulfhydryl group on the side chain of a cysteine amino acid on the antibody.

Claim 49. A pharmaceutical composition comprising the ADC or pharmaceutically  
30 acceptable salt thereof according to any one of claims 40 to 48, and a pharmaceutically acceptable carrier.


Claim 50. The ADC or pharmaceutically acceptable salt thereof according to any one of  
35 claims 40 to 48, or a pharmaceutical composition according to claim 49 for use as a medicament.

Claim 51. The ADC or pharmaceutically acceptable salt thereof, or pharmaceutical composition, for use according to claim 50, for use in the treatment or prevention of a hyperproliferative disorder, wherein the hyperproliferative disorder is cancer.

5 Claim 52. The ADC or pharmaceutically acceptable salt thereof, or pharmaceutical composition, for use according to claim 51, wherein the cancer is breast cancer, bladder cancer, lung cancer, prostate cancer, kidney cancer, esophageal carcinoma, colorectal cancer, gallbladder carcinoma, brain tumor, lymphoma, leukemia or neuroblastoma.

10 Claim 53. A drug conjugate or salt and/or solvate thereof comprising a compound of formula (I) according to any one of claims 1 to 33 and a linker, wherein the linker comprises a group capable of forming a covalent bond to a chain terminus (such as a N-terminus) or a functional group on an amino acid side chain of an antibody e.g. a sulfhydryl group.

15 Claim 54. The drug conjugate, salt and/or solvate thereof according to claim 53, wherein the drug conjugate has the formula (DC-1):



or a salt and/or solvate thereof, wherein  is a compound of formula (I) as defined in any one of claims 1 to 33, salt and/or solvate thereof.

20

Claim 55. The drug conjugate according to claim 54, wherein the drug conjugate is (1S,2R,3S,4R,5R)-5-(4-{{[6-(3,4-difluoro-2-{2-[3-(1-hydroxy-2,2-dimethylpropyl)-1,5-dimethyl-1H-pyrazol-4-yl]ethoxy}phenyl)imidazo[1,2-a]pyridine-3-yl]methyl}(methyl)carbamoyl)oxy)methyl)-2-[3-(3-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-


CC1(C)C(C(=O)O[C@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H]2O)OC(=O)c3ccc(NC(=O)CCNC(=O)CCOCCOCCN4C(=O)C=CC4=O)cc3COC(=O)N(C)Cc5cnc6ccc(cc56)c7cc(F)c(F)cc7COC8C(C)C(C)C(C)C8c9c(C)c(C)n(C)n9

5

(DC-2),

10

15



or a salt thereof.

Claim 58. A method for the preparation of an antibody drug conjugate, which comprises  
 5 covalently bonding the drug conjugate or salt thereof according to any one of claims 53 to 57  
 to an antibody.

Claim 59. The method according to claim 58, wherein the linker of the drug conjugate  
 forms a bond with a sulfur atom of the antibody that is derived from a sulfhydryl group of a  
 10 cysteine amino acid on the antibody.